Alebund Pharmaceutical raised $75 million in Series C funding led by unnamed healthcare fund to support development and commercial activities of its renal disease pipeline.

Jan 07, 2025•12 months ago

Amount Raised

$75 Million

Round Type

series c

ShanghaiPharmaceuticalBiotechnologyHealth Care

Investors

Kingray CapitalYangzhou Guojin Investment GroupUnnamed Healthcare Fund

Description

Alebund Pharmaceutical secured RMB 550 million (approximately $75 million) in a Series C funding round. The proceeds will assist in the firm's Chinese new drug application and global pivotal study for its iron-based phosphate binder AP301, among other expansion efforts.

Company Information

Company

Alebund Pharmaceutical

Location

Shanghai, Shanghai, China

About

Alebund was incubated in Shanghai in 2018. It focuses on the discovery, development, production and commercialization of novel therapies primarily for kidney diseases and their complications, as well as other chronic conditions, to bring greater therapeutic options to patients in China and globally. Alebund has built a diversified and balanced pipeline of drug candidates targeting a range of renal indications, including chronic kidney disease (CKD)/dialysis complications, IgA nephropathy, diabetic kidney disease, focal segmental glomerulosclerosis (FSGS) and autosomal dominant polycystic kidney disease (ADPKD). Alebund's small molecule manufacturing site in Yangzhou has completed construction and has been in service. Alebund has also established a dedicated commercialization team in China, responsible for the commercial promotion of renal products.

Related People

2 contacts

Funding Insights

Based on industry data

VC-backed spending patterns

VC-backed companies spend 89% more on sales and 100% more on marketing than bootstrapped peers

Tech investment trends